Proteostasis Therapeutics IPO Advisory
Share this IPO Profile:
Smart Search
Company |
Symbol |
Price Range |
Issue Price |
Open |
Shares |
Trade Date |
Proteostasis Therapeutics | PTI - NASDAQ |
$12.00-$14.00 |
$8.00 |
$8.00 | 6.25 million | 2/11/2016 |
Leerink Partners, RBC Capital Markets |
Co-Manager(s): Baird, H.C. Wainwright & Co. |
Health Care |
Filing(s): Filed 2015-12-23 Terms Added 2016-02-01
|
For IPO Boutique's "scale of 1 to 5" BUY rating on Proteostasis Therapeutics, and our comprehensive analysis, click "Buy Market Research".
Proteostasis Therapeutics Quote & Chart - Click for current quote -
PTI
About Proteostasis Therapeutics (adapted from Proteostasis Therapeutics prospectus):
They are an innovative biopharmaceutical company committed to the discovery and development of novel therapeutics that treat diseases caused by an imbalance in the proteostasis network, a set of pathways that control protein biosynthesis, folding, trafficking and clearance.
This description is adapted from prospectus. This description is not intended to be a recommendation to buy stock from this company. To see the company's full description, view their prospectus.
IPO Boutique aggregates information on public companies and private companies, such as "PTI" IPO, which is intended to educate our readers and help them evaluate potential investment opportunities and market conditions. We endeavor to research the financial industry and obtain independent verification of factual statements before presenting them to our users. Be informed.
© 2005 - 2024 IPO Boutique. All Rights Reserved